OBI Parma Inc.’s Cancer Drug OBI-3424 Phase II Trial Enrollment Halted, but Development Plans Remain Intact

Taiwan's OBI Pharma, Inc. announced on the 11th that its board of directors has approved a resolution to halt enrollment in the Phase II clinical trial of its anti-cancer drug OBI-3424. However, OBI Pharma emphasized that the development plan for OBI-3424 has not been entirely terminated, and collaboration with other partners in clinical trials will continue